key: cord-1048076-pigvetce authors: de Bruijn, Sévérine; Maes, Marie‐Berthe; De Waele, Laure; Vanhoorelbeke, Karen; Gadisseur, Alain title: First report of a de novo iTTP episode associated with an mRNA‐based anti‐COVID‐19 vaccination date: 2021-06-08 journal: J Thromb Haemost DOI: 10.1111/jth.15418 sha: 0314e53fe7dbad980a6fbc3ca083017a6cf83ae1 doc_id: 1048076 cord_uid: pigvetce Thrombotic thrombocytopenic purpura (TTP) is a rare but potentially life‐threatening thrombotic microangiopathy (TMA), characterized by disseminated thrombus formation in the microvasculature, causing severe organ failure. Immune‐mediated TTP is occasionally described after vaccination, especially against viral agents. We report a case of a 38‐year old woman with a de novo iTTP after exposure to the mRNA‐based anti‐COVID‐19 vaccine produced by Pfizer‐BioNTech. She presented with increased bruising and petechiae, starting 2 weeks after receiving the first dose of the anti‐COVID‐19 vaccine. Laboratory data revealed a severe ADAMTS13‐deficiency in combination with a very high autoantibody titer against ADAMTS13. She was successfully treated with plasma exchange, corticosteroids, rituximab and Caplacizumab. To our knowledge, this is the first case report of iTTP post mRNA‐based COVID‐19‐vaccination in a previously TTP‐naïve patient. Thrombotic thrombocytopenic purpura (TTP) is a rare but potentially life-threatening thrombotic microangiopathy (TMA) characterized by disseminated thrombus formation in the microvasculature, leading to microangiopathic hemolytic anemia, profound thrombocytopenia and organ failure [1] . It is caused by a severe deficiency (activity level 10%) of the von Willebrand Factor (vWF)-cleaving protease ADAMTS13. In the more rare congenital TTP, ADAMTS13 deficiency is the result of homozygous or compound heterozygous mutations in the ADAMTS13 gene [2, 3] . Predominantly, TTP is the result of immune-mediated inhibition and/of clearance of ADAMTS13 (immune-mediated TTP/iTTP), leading to excessive levels of ultra-large vWF (ULVWF) multimers, which are responsible for binding and removal of platelets, and ultimately to microthrombosis and thrombocytopenia [4, 5] . Due to diffuse tissue ischemia and organ dysfunction, through scattered microthrombi, particularly affecting brain, heart and kidneys, iTTP has a high mortality rate up to 90% if left untreated. With plasma exchange (PEX) and immunosuppressive strategies as the standard of care, the survival rate improved to 80% [2, 6] . Immune-mediated TTP mainly affects otherwise young and healthy adults and is characterized by a female-to-male ratio of 2:1 to 3.5:1 with peak incidences in the third to fifth decades of life. The reported annual incidence is between 1.5 and 6.0 cases per million and an average annual prevalence of 10 cases per million in Europe, accounting for over 95 % of all TTP cases [6, 7] . Several events, including malignancies, pregnancy, medication, viral infections and vaccinations, can trigger production of anti-ADAMTS13 antibodies. To the best of our knowledge, here we describe the first case report of a de novo iTTP associated with an mRNA-based anti-COVID-19 vaccination. This article is protected by copyright. All rights reserved Accepted Article 2 A 38-year-old Caucasian female, without significant medical history or medication, was referred to the Hematology department because of progressive thrombocytopenia since one week, and spontaneous bruising and petechiae since several weeks. Further anamnesis revealed blurred vision in the left eye since 2 weeks. As care worker, she had already received both doses of the nucleoside modified messenger RNA (mRNA) BNT162b2 anti-COVID-19 vaccine (Pfizer-BioNTech, (Comirnaty®)), respectively 6 and 3 weeks earlier. The first bruises had been noticed two weeks after the first dose of the vaccination, but these had been ascribed to minor traumas from working in the operating theatre and no further action was taken. However, because of increased bruising after the second dose, blood sampling was done, showing a thrombocytopenia of 57x10 9 /L. The thrombocytopenia deepened over the following week and the patient was referred to the Antwerp University Hospital. On referral, apart from diffuse ecchymosis, physical examination was normal. However, ophthalmological examination showed signs of central serous chorioretinopathy, caused by plateletrich microthrombus formation in the choroid vasculature, as an ocular manifestation related to TTP [8] . Initial blood results were also indicative of TTP, with a PLASMIC score of six (Supporting information). More extensive work-up revealed a severe ADAMTS13-deficiency with undetectable levels of ADAMTS13 enzyme activity (Technozym ADAMTS13 activity ELISA kit; Technoclone), confirming the TTP diagnosis. A very high titer of autoantibodies (106 BU) was measured by a functional Bethesda method and confirmed by a general ADAMT13 inhibitor ELISA (Technozym ADAMTS13 INH ELISA kit; Technoclone) showing an antibody titer of > 1000 AU/mL. Epitope mapping revealed a classical iTTP immunoprofile with only antibodies against the cysteine/spacer (CS) domains of ADAMTS13 [9] . Further analysis revealed an open ADAMTS13 conformation (conformation index (CI) > 0.5), both spontaneously (CI 2.94) and after addition of activating anti-CUB1 17G2 antibodies (CI 3.08), which is a hallmark of acute iTTP [10, 11] . Antibodies to platelet factor 4 (PF4)-heparin complex were negative, using HIT testing (HemosIL AcuStar HIT IgG assay, Werfen and Zymutest HIA IgG, Hyphen This article is protected by copyright. All rights reserved Accepted Article 2 The patient was urgently admitted for treatment with daily PEX using fresh frozen plasma (FFP; 1.5 x total plasma volume) in combination with methylprednisolone 1000 mg daily for three consecutive days. This resulted in prompt normalisation of the biochemical parameters and on day 2 low dose acetylsalicylic acid (LDA) was started. Methylprednisolone was stopped on day 3 and on day 5 the daily PEX sessions were reduced to every other day since there were no signs of hemolysis or clinical deterioration and the platelet count was above 150 x 10 9 /L for two consecutive days (Figure 1) . Unfortunately, on day 8 the platelet count dropped significantly with raised LDH values, leading to a restart of methylprednisolone 1000 mg daily for three consecutive days followed by a corticosteroids tapering schedule, and intensification of PEX therapy (daily) in association with rituximab (375 mg/m²) once a week for a total of 4 weeks. This resulted in high and stable thrombocyte levels (> 400 x 10 9 /L ) but persistently undetectable ADAMTS13 activity. The beneficial effect of PEX was ascribed to removal of ULVWF multimers, rather than to administration of ADAMTS13 in the FFP. PEX was reduced to every other day on day 12 and discontinued on day 25. Given the persistent low ADAMTS13 activity level after 17 PEX sessions, Caplacizumab 10 mg was started once daily on day 18, and LDA discontinued. On day 20, her titer of autoantibodies had already fallen sharply but still remained high (22 BU). On day 29, after 12 consecutive days of Caplacizumab therapy, the patient could be discharged from the hospital. Currently, the patient is monitored on an outpatient basis with periodic blood cell counts and is clinically well. However, ADAMTS13 remains undetectable with a high antibody titer (42 BU). This article is protected by copyright. All rights reserved This is mediated by platelet-activating antibodies against platelet-factor 4, clinically resembling autoimmune heparin-induced thrombocytopenia (HIT) [12] [13] [14] [15] . So far, VITT has not been reported after exposure to the mRNA-based vaccines. We now describe the first published case of a de novo iTTP after exposure to the mRNA-based reported a TTP episode 24 hours after typhoid vaccination, suggesting vaccination as triggering factor [18] . Since then some rare iTTP episodes have been documented after vaccination, particularly against viral agents [19] [20] [21] [22] [23] [24] [25] . The causal association was mainly suggested by the fact that no other underlying precipitating causes were present and because of a clear time-correlation. The time from vaccination to onset of TTP was between 5-14 days in cases of TTP after influenza vaccination [20, [23] [24] [25] and 15 days after administration of a rabies vaccine and a 23-valent pneumococcal polysaccharide vaccine [21, 22] . In the latter, the authors suggest that polysaccharide antigens present in the pneumococcal vaccine or adjuvants may have contributed to the formation of the inhibitor against ADAMTS13 through cross-reactivity [22] . In the current case petechiae/bruising gradually occurred two weeks after first dose of the Pfizer- Clinical practice. Thrombotic thrombocytopenic purpura Thrombotic thrombocytopenic purpura Characterization and treatment of congenital thrombotic thrombocytopenic purpura Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies An update on pathogenesis and diagnosis of thrombotic thrombocytopenic purpura Incidence of acquired thrombotic thrombocytopenic purpura in Germany: a hospital level study Thrombotic thrombocytopenic purpura Retinal involvement in acute thrombotic thrombocytopenic purpura: a case report Pathogenicity of Anti-ADAMTS13 Open ADAMTS13, induced by antibodies, is a biomarker for subclinical immune-mediated thrombotic thrombocytopenic purpura An open conformation of ADAMTS-13 is a hallmark of acute acquired thrombotic thrombocytopenic purpura Vaccine-induced immune thrombotic thrombocytopenia (VITT): targeting pathomechanisms with Bruton tyrosine kinase inhibitors Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination Post adenoviral-based COVID-19 vaccines thrombosis: A proposed mechanism Relapse of thrombotic thrombocytopenic purpura after COVID-19 vaccine Thrombotic Thrombocytopenic Purpura after Ad26.COV2-S Vaccination Simultaenous thrombotic thrombocytopenic pupura and agammaglobulinaemia The Lancet Vaccination and Thrombotic Thrombocytopenic Purpura Thrombotic thrombocytopenic purpura after influenza vaccination Rabies vaccine-associated thrombotic thrombocytopenic purpura Acute thrombotic thrombocytopenic purpura after pneumococcal vaccination Thrombotic thrombocytopenic purpura following influenza vaccination--a brief case report Refractory thrombotic thrombocytopenic purpura following influenza vaccination The authors would like to acknowledge Dr. Bart Peeters, clinical biologist at the Department of Clinical Biology, for his valuable help regarding the COVID-19 serological test results. The authors declare that they have no conflict of interest Additional supporting information may be found online in the Supporting Information section at the and of this article. This article is protected by copyright. All rights reserved Accepted Article